IconOVir Bio is dedicated to advancing cancer treatment through innovative therapeutic approaches. The company focuses on developing oncolytic virus therapies, which utilize genetically modified viruses to selectively target and destroy cancer cells while sparing healthy tissue. This method not only aims to directly kill tumors but also to stimulate the immune system, enhancing the body’s natural ability to fight cancer. By harnessing the power of these oncolytic viruses, IconOVir Bio seeks to improve patient outcomes and provide new hope for those affected by various forms of cancer.

In addition to oncolytic virus therapies, IconOVir Bio is committed to a robust pipeline of products that leverage cutting-edge scientific research. The company emphasizes a multi-faceted approach to cancer treatment, integrating advanced technologies to optimize therapeutic efficacy. Their research focuses on understanding the tumor microenvironment and the interactions between cancer cells and the immune system, which is crucial for developing effective treatments. Through these innovative strategies, IconOVir Bio aims to push the boundaries of cancer therapy and ultimately fulfill its mission of curing cancer and restoring life to patients worldwide.

United States

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O'Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.

IconOVir Bio

Company Details